Navidea Biopharmaceuticals, Inc. (NAVB) |
0.0365 0.001 (2.82%) 03-28 15:06 |
Open: | 0.033 |
High: | 0.04133 |
Low: | 0.033 |
Volume: | 64,218 |
Market Cap: | 4(M) |
PE Ratio: | -0.18 |
Exchange: | American Stock Exchange |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 0.05 |
Resistance 1: | 0.04 |
Pivot price: | 0.04 |
Support 1: | 0.03 |
Support 2: | 0.03 |
52w High: | 0.32955 |
52w Low: | 0.021 |
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
EPS | -119300.000 |
Book Value | -0.200 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -1.00 |
Return on Assets (ttm) | 678.0 |
Return on Equity (ttm) | 791.0 |
Thu, 28 Mar 2024
StockNews.com Begins Coverage on Navidea Biopharmaceuticals (NYSE:NAVB) - Defense World
Tue, 12 Mar 2024
StockNews.com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB) - Defense World
Tue, 05 Mar 2024
What We Expect Going Forward From Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) - Insider Financial
Mon, 29 Jan 2024
Central Ohio public company voluntarily deregisters stock - Columbus Business First - The Business Journals
Fri, 01 Dec 2023
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual ... - Business Wire
Thu, 05 Oct 2023
Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |